M. D. Surman

497 total citations
17 papers, 401 citations indexed

About

M. D. Surman is a scholar working on Organic Chemistry, Molecular Biology and Pharmacology. According to data from OpenAlex, M. D. Surman has authored 17 papers receiving a total of 401 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Organic Chemistry, 7 papers in Molecular Biology and 3 papers in Pharmacology. Recurrent topics in M. D. Surman's work include Synthetic Organic Chemistry Methods (5 papers), Asymmetric Synthesis and Catalysis (5 papers) and Chemical Synthesis and Analysis (2 papers). M. D. Surman is often cited by papers focused on Synthetic Organic Chemistry Methods (5 papers), Asymmetric Synthesis and Catalysis (5 papers) and Chemical Synthesis and Analysis (2 papers). M. D. Surman collaborates with scholars based in United States, United Kingdom and Australia. M. D. Surman's co-authors include Marvin J. Miller, Mark J. Mulvihill, Wenlin Lee, Kyung‐Hee Kim, Peter R. Guzzo, Joel R. Walker, Bruce J. Sargent, David Fox, Han‐Ting Zhang and Jean Viggers and has published in prestigious journals such as Journal of Medicinal Chemistry, The Journal of Organic Chemistry and Organic Letters.

In The Last Decade

M. D. Surman

17 papers receiving 391 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. D. Surman United States 12 286 152 66 37 23 17 401
Fuk‐Wah Sum United States 11 271 0.9× 214 1.4× 51 0.8× 26 0.7× 17 0.7× 13 485
Iván Collado Spain 13 289 1.0× 259 1.7× 21 0.3× 28 0.8× 9 0.4× 17 447
David T. MacPherson United Kingdom 11 418 1.5× 104 0.7× 33 0.5× 40 1.1× 10 0.4× 24 533
José Méndez-Andino United States 11 359 1.3× 188 1.2× 29 0.4× 26 0.7× 46 2.0× 18 460
Donald L. Hertzog United States 18 518 1.8× 267 1.8× 69 1.0× 21 0.6× 69 3.0× 24 736
Takunobu Shibata Japan 11 194 0.7× 187 1.2× 154 2.3× 14 0.4× 27 1.2× 15 416
John M. Wetzel United States 14 230 0.8× 192 1.3× 40 0.6× 20 0.5× 20 0.9× 21 564
Young‐Shin Kwak South Korea 12 269 0.9× 182 1.2× 45 0.7× 44 1.2× 10 0.4× 26 485
S.Y. Sit United States 11 209 0.7× 151 1.0× 123 1.9× 9 0.2× 6 0.3× 15 415
János Éles Hungary 11 150 0.5× 92 0.6× 14 0.2× 33 0.9× 7 0.3× 34 342

Countries citing papers authored by M. D. Surman

Since Specialization
Citations

This map shows the geographic impact of M. D. Surman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. D. Surman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. D. Surman more than expected).

Fields of papers citing papers by M. D. Surman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. D. Surman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. D. Surman. The network helps show where M. D. Surman may publish in the future.

Co-authorship network of co-authors of M. D. Surman

This figure shows the co-authorship network connecting the top 25 collaborators of M. D. Surman. A scholar is included among the top collaborators of M. D. Surman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. D. Surman. M. D. Surman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Surman, M. D., et al.. (2024). Precursor Development and Aerosol‐Assisted Chemical Vapour Deposition for BiVO 4 and W‐Doped BiVO 4 Photoanodes: A Universal Ligand Approach. ChemSusChem. 18(4). e202401452–e202401452. 3 indexed citations
2.
Stokes, Michael E., M. D. Surman, Verónica Calvo, et al.. (2022). Optimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors. Pharmaceutics. 14(10). 2233–2233. 5 indexed citations
3.
Radnai, László, M. D. Surman, Erica J. Young, et al.. (2021). Discovery of Selective Inhibitors for In Vitro and In Vivo Interrogation of Skeletal Myosin II. ACS Chemical Biology. 16(11). 2164–2173. 4 indexed citations
4.
Gurney, Mark E., Richard A. Nugent, Timothy J. Hagen, et al.. (2019). Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders. Journal of Medicinal Chemistry. 62(10). 4884–4901. 56 indexed citations
5.
Moore, Nicholas, Bruce J. Sargent, Peter R. Guzzo, & M. D. Surman. (2013). From preclinical to clinical development: The example of a novel treatment for obesity. Neurobiology of Disease. 61. 47–54. 11 indexed citations
6.
Hadden, Mark, Alan J. Henderson, M. D. Surman, et al.. (2010). Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity. Bioorganic & Medicinal Chemistry Letters. 20(23). 7020–7023. 11 indexed citations
7.
Surman, M. D., Emily Freeman, Mark Hadden, et al.. (2010). 5-(Pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists. Bioorganic & Medicinal Chemistry Letters. 20(23). 7015–7019. 14 indexed citations
8.
Henderson, Alan J., Mark Hadden, Yuri L. Khmelnitsky, et al.. (2010). Tetrahydrocarboline analogs as MCH-1 antagonists. Bioorganic & Medicinal Chemistry Letters. 20(23). 7024–7028. 10 indexed citations
9.
Voss, Matthew E., David D. Manning, Xinchao Chen, et al.. (2008). Synthesis and SAR of vinca alkaloid analogues. Bioorganic & Medicinal Chemistry Letters. 19(4). 1245–1249. 23 indexed citations
10.
Surman, M. D. & R. H. Hutchings. (2005). Azepines, Cyclopentazepines, and Phosphorus Analogues. ChemInform. 36(24). 1 indexed citations
11.
Surman, M. D., Mark J. Mulvihill, & Marvin J. Miller. (2002). Regio- and Stereoselective Ring Openings of 3-Aza-2-oxabicyclo[2.2.1]hept-5-ene Systems with Copper Catalyst-Modified Grignard Reagents:  Application to the Synthesis of an Inhibitor of 5-Lipoxygenase. The Journal of Organic Chemistry. 67(12). 4115–4121. 47 indexed citations
12.
Surman, M. D., Mark J. Mulvihill, & Marvin J. Miller. (2002). Novel α-substituted β-amino diesters from acylnitroso-derived hetero-Diels–Alder cycloadducts. Tetrahedron Letters. 43(7). 1131–1134. 24 indexed citations
13.
14.
Surman, M. D., Mark J. Mulvihill, & Marvin J. Miller. (2001). Novel 1,4-Benzodiazepines from Acylnitroso-Derived Hetero-Diels−Alder Cycloadducts. Organic Letters. 4(1). 139–141. 47 indexed citations
15.
Surman, M. D. & Marvin J. Miller. (2001). Regio- and Stereochemically Controlled Formation of Hydroxamic Acid Containinganti- orsyn-1,4-Cycloalkenols from Acylnitroso-Derived Diels−Alder Adducts. The Journal of Organic Chemistry. 66(7). 2466–2469. 39 indexed citations
16.
Surman, M. D. & Marvin J. Miller. (2001). Synthesis of a Conformationally Restricted Substrate Analogue of Siderophore Biosynthetases. Organic Letters. 3(4). 519–521. 32 indexed citations
17.
Mulvihill, Mark J., M. D. Surman, & Marvin J. Miller. (1998). Regio- and Stereoselective Fe(III)- and Pd(0)-Mediated Ring Openings of 3-Aza-2-oxabicyclo[2.2.1]hept-5-ene Systems. The Journal of Organic Chemistry. 63(15). 4874–4875. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026